During the month of February 2022, University of Pittsburgh innovators were issued eight U.S. patents.  Five of those patents were based on research work conducted by McGowan Institute for Regenerative Medicine affiliated faculty members.  Their newly issued patents include:

Treatment of Ocular Conditions Utilizing a Histone/Protein Deacetylase Inhibitor: Steven Little; Michelle Ratay (U.S. Patent No. 11,253,480)

Methods and Compositions for Diagnosis and Prognosis of Renal Injury and Renal Failure: Alexander Zarbock; Paul McPherson; John Kellum Jr. (U.S. Patent No. 11,243,202)

Management of Acute Kidney Injury Using Insulin-like Growth Factor-Binding Protein 7 and Tissue Inhibitor of Metalloproteinase 2: John Kellum Jr.; James Kampf; Paul McPherson (U.S. Patent No. 11,243,217)

Chemical Inhibition of the E3 Ligase Subunit FBX07 Confers Neuroprotection and Anti-Inflammatory Activity by Stabilizing Mitochondria: Yuan Liu; Beibei Chen; Rama Mallampalli; Charleen Chu (U.S. Patent No. 11,242,339)

Thermoresponsive Hydrogel Containing Polymer Microparticles for Noninvasive Ocular Drug Delivery: Morgan Fedorchak; Steven Little; Joel Schuman; Anthony Cugini (U.S. Patent No. 11,246,838)

Congratulations on these successful developments!

Illustration:  U.S. Patent and Trademark Office logo.

Read more…

Innovation Institute News Release